<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10839290</article-id><article-id pub-id-type="pmc">2363221</article-id><article-id pub-id-type="pii">6691138</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1138</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Propper</surname><given-names>D J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Levitt</surname><given-names>N C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>O'Byrne</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Braybrooke</surname><given-names>J P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Talbot</surname><given-names>D C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ganesan</surname><given-names>T S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>C H</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rajagopalan</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Littlewood</surname><given-names>T J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dixon</surname><given-names>R M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Harris</surname><given-names>A L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>ICRF Medical Oncology Unit, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK</aff><aff id="aff2"><label>2</label>Department of Haematology, Oxford-Radcliffe NHS Trust, Oxford, OX3 9DU, UK</aff><aff id="aff3"><label>3</label>Medical Research Council Biochemical and Clinical Magnetic Resonance Unit, Oxford-Radcliffe NHS Trust, Oxford, OX3 9DU, UK</aff><pub-date pub-type="ppub"><month>06</month><year>2000</year></pub-date><volume>82</volume><issue>11</issue><fpage>1776</fpage><lpage>1782</lpage><history><date date-type="received"><day>01</day><month>06</month><year>1999</year></date><date date-type="rev-recd"><day>16</day><month>02</month><year>2000</year></date><date date-type="accepted"><day>17</day><month>02</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>BW12C (5-[2-formyl-3-hydroxypenoxyl] pentanoic acid) stabilizes oxyhaemoglobin, causing a reversible left-shift of the oxygen saturation curve (OSC) and tissue hypoxia. The activity of mitomycin C (MMC) is enhanced by hypoxia. In this phase II study, 17 patients with metastatic colorectal cancer resistant to 5-fluorouracil (5-FU) received BW12C and MMC. BW12C was given as a bolus loading dose of 45 mg kg<sup>&#x02212;1</sup>over 1 h, followed by a maintenance infusion of 4 mg kg<sup>&#x02212;1</sup>h<sup>&#x02212;1</sup>for 5 h. MMC 6 mg m<sup>&#x02212;2</sup>was administered over 15 min immediately after the BW12C bolus. The 15 evaluable patients had progressive disease after a median of 2 (range 1&#x02013;4) cycles of chemotherapy. Haemoglobin electrophoresis 3 and 5 h after the BW12C bolus dose showed a fast moving band consistent with the BW12C-oxyhaemoglobin complex, accounting for approximately 50&#x00025; of total haemoglobin. The predominant toxicities &#x02013; nausea/vomiting and vein pain &#x02013; were mild and did not exceed CTC grade 2. Liver<sup>31</sup>P magnetic resonance spectroscopy of patients with hepatic metastases showed no changes consistent with tissue hypoxia. The principle of combining a hypoxically activated drug with an agent that increases tissue hypoxia is clinically feasible, producing an effect equivalent to reducing tumour oxygen delivery by at least 50&#x00025;. However, BW12C in combination with MMC for 5-FU-resistant colorectal cancer is not an effective regimen. This could be related to drug resistance rather than a failure to enhance cytotoxicity. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>bioreductive agent potentiation</kwd><kwd>MRS</kwd><kwd>ATP</kwd></kwd-group></article-meta></front></article>


